The new FX humeral head will provide enhanced flexibility for surgeons to match the anatomy of patients. Credit: FX Solutions / PRNewswire.

FX Solutions has received US Food and Drug Administration (FDA) 510k approval for its new FX V135 shoulder arthroplasty platform.

The FX V135 platform is a 70mm humeral stem, which is proximally coated with hydroxyapatite (HAP).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It features suture holes proximally for soft tissue repair as well as Titanium Nitride (TiN) coated and uncoated Cobalt Chrome (CoCr) humeral heads and glenospheres.

The platform also includes unique net-shape moulded humeral cups and 12 different baseplate options in the reverse construct.

It comprises a new-to-market mini stem humeral component that can be aligned at 135° for the reverse and anatomical configurations.

The company’s net-shape moulded humeral cups will allow surgeons to perform reverse construct using an asymmetric humeral cup to change the inclination to 145°.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

FX Solutions CEO Baptiste Martin said: “The FX V135 was designed to allow surgeons to tailor our system to the patient – rather than the patient to our system.

“Across our portfolio, now, surgeons are able to lateralise or medialise on both the humeral and glenoid side of the procedure.

“The FX V135 has been long awaited, and we are eager to get this rolled out to the market and continue to grow our market share.”

The FX V135 anatomical configuration includes a taper component, which enables 360° of eccentricity.

This provides for a dual eccentricity offering between the humeral head components and taper.

FX stated that it is introducing the humeral head components with variable head heights to provide enhanced flexibility for surgeons to match the anatomy of patients.